499 related articles for article (PubMed ID: 23642545)
1. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
[TBL] [Abstract][Full Text] [Related]
3. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
[TBL] [Abstract][Full Text] [Related]
4. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
Lescaille G; Coudert AE; Baaroun V; Ostertag A; Charpentier E; Javelot MJ; Tolédo R; Goudot P; Azérad J; Berdal A; Spano JP; Ruhin B; Descroix V
Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Hess G; Borker R; Fonseca E
Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
[TBL] [Abstract][Full Text] [Related]
6. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
[TBL] [Abstract][Full Text] [Related]
7. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Bozas G; Roy A; Ramasamy V; Maraveyas A
Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
[TBL] [Abstract][Full Text] [Related]
10. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
[TBL] [Abstract][Full Text] [Related]
14. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P
Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132
[TBL] [Abstract][Full Text] [Related]
15. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
18. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
[TBL] [Abstract][Full Text] [Related]
20. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
